Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Verve Therapeutics CEO to participate in fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The company is pioneering a new approach to cardiovascular disease with single-course gene editing medicines.
02/01/2024 - 06:30 AM
BOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 11:30 a.m. ET in New York.
A live webcast will be available in the investor section of the company's website at www.vervetx.com . The webcast will be archived for 30 days following the presentation.
About Verve Therapeutics
Investor Contact jrobinson@vervetx.com
Media Contact ashlea@1abmedia.com
What is the latest event announced by Verve Therapeutics?
Verve Therapeutics CEO Sekar Kathiresan will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference.
When and where will the fireside chat take place?
The fireside chat will take place on Thursday, February 8, 2024, at 11:30 a.m. ET in New York.
Where can I watch the live webcast of the event?
The live webcast will be available in the investor section of the company's website at www.vervetx.com.
How long will the webcast be available for viewing after the presentation?
The webcast will be archived for 30 days following the presentation.
VERV Rankings
#5259 Ranked by Stock Gains
VERV Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About VERV
verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.
